Open-label, Phase 1 Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 02 Oct 2017
At a glance
- Drugs Natural killer cell therapy (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Acronyms QUILT-3.028
- Sponsors NantKwest
- 02 Oct 2017 According to a NantKwest media release, first patient has been treated.
- 23 Aug 2017 Status changed from not yet recruiting to recruiting.
- 25 Jan 2017 New trial record